MedTrace Logo

Long-Term Assessment of Safety and Physical Function With AMG 108 in RA

NCT00369473 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 690

Last updated 2016-12-13

No results posted yet for this study

Summary

The purpose of this study is to assess long-term safety of SC AMG 108 in the treatment of RA

Conditions

Interventions

DRUG

AMG 108

125 mg via SC (subcutaneous) injection every 4 weeks

DRUG

AMG 108

250 mg via SC (subcutaneous) injection every 4 weeks

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-06-30
Completion
2008-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00369473 on ClinicalTrials.gov